Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

November 14, 2025

Consolidated Financial Results for the Nine Months Ended September 30, 2025 (IFRS) (Q3 FY ending December 2025)

Company name: NIKKISO CO., LTD.
Stock exchange listing: Tokyo Stock Exchange
Stock code: 6376
URL: https://www.nikkiso.com
Representative: Koichi Kato, Representative Director, President & CEO
Contact: Masaharu Murakami, Executive Officer, Head of Corporate Unit
Tel. +81-3-3443-3711

Scheduled date of commencement of dividend payment: —
Supplementary material of quarterly financial results: Yes
Quarterly financial results briefing: None

(Amounts of less than one million yen are rounded down.)

1. Consolidated Financial Results for the Nine Months Ended September 30, 2025 (January 1, 2025 – September 30, 2025)

(1) Consolidated Operating Results (cumulative) (Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Profit for the period	
Nine months ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
September 30, 2025	152,278	0.4	8,211	119.6	7,985	72.7	7,402	79.4
September 30, 2024	151,708	13.6	3,739	119.9	4,622	(46.1)	4,126	(35.7)

	Profit for the period attributable to owners of the company		Total comprehensive income		Basic earnings per share	Diluted earnings per share
Nine months ended	Million yen	%	Million yen	%	Yen	Yen
September 30, 2025	7,331	75.0	9,809	72.6	110.65	110.51
September 30, 2024	4,188	(33.2)	5,685	(55.5)	63.26	63.18

(2) Consolidated Financial Position

	Total assets	Total equity	Equity attributable to owners of parent	Ratio of equity attributable to owners of parent to total assets
As of	Million yen	Million yen	Million yen	%
September 30, 2025	328,354	149,531	147,706	45.0
December 31, 2024	325,563	142,005	140,070	43.0

2. Dividend Conditions

	Dividends per share				
	End of first quarter	End of second quarter	End of third quarter	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
FY 2024	—	15.00	—	15.00	30.00
FY 2025	—	18.00	—		
FY 2025 (Forecast)			—	18.00	36.00

Note) Revisions to the latest dividend forecasts: None

3. Consolidated Financial Forecasts for the Fiscal Year Ending December 31, 2025 (January 1, 2025 - December 31, 2025)

(Percentages indicate year-on-year changes.)

	Revenue		Operating profit		Profit before tax		Profit for the period attributable to owners of the company		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Annual	230,500	8.0	14,000	118.8	14,700	46.9	11,300	42.0	170.63

Note) Revisions to the latest financial forecasts: None
For further details, please refer to "1. Qualitative Information on Quarterly Financial Results (3) Summary of Outlook for Consolidated Financial Forecast".

* Note
(1) Significant changes in the scope of consolidation during the period：Yes
Newly included: None
Excluded: Six companies（Nikkiso Critical Care Medical Supplies (Shanghai) Co., Ltd, Nikkiso Europe GmbH and its 4 subsidiaries）

(2) Changes in accounting policies and accounting estimates

(i) Changes in accounting policies required by IFRS: None
(ii) Changes in accounting policies other than (i): None
(iii) Changes in accounting estimates: None

(3) Number of ordinary shares issued

(i) Total number of issued shares at the end of the period (including treasury shares)

As of September 30, 2025	69,175,664 shares
As of December 31, 2024	69,175,664 shares

(ii) Number of treasury shares at the end of the period

As of September 30, 2025	2,908,919 shares
As of December 31, 2024	2,926,424 shares

(iii) Average number of shares outstanding during the period

Nine months ended September 30, 2025	66,259,696 shares
Nine months ended September 30, 2024	66,215,823 shares

*The consolidated financial results are out of scope of the quarterly review procedure by certified public accountants or an auditing firm.

* Disclaimer regarding forward-looking information including appropriate use of financial forecasts
The forecast statements shown in this material are based on information currently available and certain assumptions that the Company regards as reasonable. The Company does not promise or guarantee the achievement of these forecasts. Actual performance and other results may differ significantly from these forecast figures due to various factors.

1. Qualitative Information on Quarterly Financial Results

(1) Summary of Operating Results

(i) Overview of Financial Results

During the nine months ended September 30, 2025, the business environment surrounding the Nikkiso Group (the "Group") showed progress toward the normalization of production capacity among aircraft manufacturers. However, the external environment remained unpredictable due to the factors, including the U.S. tariff increases and price hikes, growing supply-chain uncertainty stemming from heightened U.S.-China tensions, and a demand decline in the domestic hemodialysis market.

In the LNG sector, the Industrial Business's primary market, capital investment demand remains on an upward trend in the medium to long term due to growing emphasis on the reassessment of the U.S. climate change policy and energy security. On the other hand, the next-generation energy sector shows regional disparities in market growth rates and investment appetite, both affected by the movement of the climate change policy and geopolitical factors.

In the Aerospace Business, driven by recovering demand in the aircraft industry, production capacity has been increasing through supply-chain restructuring. However, uncertain supply conditions caused by component supply delays and labor shortages continued to persist. With these challenges being progressively addressed, the industry's overall production capacity is gradually recovering.

In the hemodialysis market, the Medical Business's core market, domestic medical institutions continue to take a conservative approach to capital investment. In overseas markets, demand has been recovering in China while remaining steady in Europe. In other Asian regions, the market is growing due to increasing patient numbers and improving healthcare standards.

Under these circumstances, the performance of each business for the nine months ended September 30, 2025 is summarized below: the Industrial Business increased its year-on-year profit, driven by steady execution of booked orders, high-profit projects, and sales price adjustment in Industrial Pumps and System Business. After experiencing revenue and profit declines through the first half of FY2025 due to the delayed supply-chain recovery, the Aerospace Business achieved both revenue and profit growth in the nine months ended September 30, 2025, led by industry-wide production recovery. The Medical Business increased its year-on-year profit, driven by the overseas hemodialysis business.

As a result, the Group's consolidated financial results for the nine months ended September 30, 2025 were as follows: Orders received totaled ¥163,748 million (-4.7% YoY), revenue amounted to ¥152,278 million (+0.4% YoY), and operating profit amounted to ¥8,211 million (+119.6% YoY). Overall revenue increased slightly year-on-year, despite the loss of revenue from the CRRT business transfer. Operating profit improved substantially, reflecting steady business expansion across all business segments.

The Group recorded foreign exchange losses of ¥640 million due to yen appreciation (compared to foreign exchange gains of ¥316 million in the nine months ended September 30, 2024), resulting in profit before tax of ¥7,985 million (+72.7% YoY), and profit for the period attributable to owners of the company, amounting to ¥7,331 million (+75.0% YoY).

(ii) Results by Segment

(unit: millions of yen)

			Nine Months ended September 30, 2024	Nine Months ended September 30, 2025	Year on Year	
					Change	Rate of change
Orders received			171,829	163,748	(8,081)	(4.7%)
	Industrial Unit		111,436	106,043	(5,392)	(4.8%)
		Industrial Business	98,547	93,027	(5,520)	(5.6%)
		Aerospace Business	12,286	12,730	+443	+3.6%
	Medical Unit		60,579	57,914	(2,665)	(4.4%)
Revenue			151,708	152,278	+569	+0.4%
	Industrial Unit		92,839	96,142	+3,303	+3.6%
		Industrial Business	80,256	83,152	+2,896	+3.6%
		Aerospace Business	12,009	12,708	+698	+5.8%
	Medical Unit		59,030	56,336	(2,694)	(4.6%)
Business profit			3,739	8,211	+4,472	+119.6%
	Industrial Unit		4,268	7,257	+2,989	+70.0%
		Industrial Business	6,318	7,478	+1,159	+18.4%
		Aerospace Business	(212)	10	+223	—
	Medical Unit		2,287	3,784	+1,496	+65.4%
	Corporate Expenses		(2,949)	(2,960)	(10)	—
Profit before tax			4,622	7,985	+3,362	+72.7%
Profit for the period attributable to owners of the company			4,188	7,331	+3,143	+75.0%

*The total for the Industrial Unit includes the amount for the deep ultraviolet LED Business.
*In accordance with the organizational change effective January 1, 2025, the segment results for the nine months ended September 30, 2024 reflect the figures after the organizational restructuring.
*The amount for each segment is shown before elimination of intersegment transactions.

≪Business Environment and Performance by Business Segment≫

Business	Main Products	Business and Orders Environment for the nine months ended September 30, 2025	Business Performance for the nine months ended September 30, 2025
Industrial Business	Machines and Equipment Relating to Industrial Gas and Liquid Gas	・With growing emphasis on the reassessment of the U.S. climate change policy and energy security, the LNG sector is expected to see medium to long term demand growth. Projects for liquefaction plants and import terminals across North America, Europe, and Asia continue to show strong momentum. ・The next-generation energy sector, including hydrogen and ammonia, has been affected by geopolitical factors, resulting in regional disparities in market growth rates and investment appetite.	Regarding the Clean Energy & Industrial Gases group (the "CE & IG group"), the leading business player, ・both revenue and gross profit increased through steady execution of booked orders. ・profit declined due to increased fixed costs for organizational development. ・Technology and product development for the low-carbon/decarbonization market continues, along with organizational development.
	Industrial Pumps and System	・Orders received exceeded the previous year's level, with efforts now focused on backlog execution.	・High-margin projects and sales price adjustments are driving sustained profitability improvement.
	Precision Equipment	・In the electronic components market, while the capex adjustment phase still continues, orders received remain on a par with FY2024.	・Profit increased slightly year-on-year.
Aerospace Business	Carbon Fiber Reinforced Plastic (CFRP) Moldings for Commercial Aircrafts	・Driven by recovering demand in the aircraft industry, production capacity has been increasing through supply-chain restructuring. However, uncertain supply conditions caused by component supply delays and labor shortages continued to persist. With these challenges being progressively addressed, the industry's overall production capacity is gradually recovering.	・Revenue increased year-on-year due to increased shipment of the core cascade product, following increased production volume in the entire industry. ・Despite the profit decline factor of yen appreciation, profit increased year-on-year due to improvement of product mix and impact of increased revenue.
Medical Business	Hemodialysis Machines	・While the number of domestic hemodialysis patients may shift to a gradual downward trend over the medium to long term, it is expected to remain unchanged in the near term. ・In the Chinese market, which has the world's largest number of patients, market growth is expected through	・Domestic sales of hemodialysis machines fell below FY2024 levels due to the continued conservative approach to capital investment among medical institutions. ・Overseas sales increased in both revenue and profit year-on-year attributable to recovery from demand

		expanding capital investment demand. Meanwhile, advancing localization policies have led to more local manufacturers and a shifting competitive environment. ・In Asian regions outside China, market growth is expected to continue, driven by economic development and medical infrastructure improvements.	decline in China and sales expansion in Europe. ・As part of the U.S. market expansion, sales approval for hemodialysis machines was obtained in May 2025. As the next step, the Group is preparing to apply for regulatory approval of a higher-end, multifunctional hemodialysis machine.

(2) Qualitative Information on Consolidated Financial Position

As of September 30, 2025, total assets increased by ¥2,790 million from the end of the previous consolidated fiscal year to ¥328,354 million, mainly due to an increase in long-term financial assets despite a decrease in assets held for sale.

As of September 30, 2025, total liabilities decreased by ¥4,735 million from the end of the previous consolidated fiscal year to ¥178,822 million. The main factor was the decrease in short-term and long-term borrowings, while lease liabilities increased.

As of September 30, 2025, total equity increased by ¥7,525 million from the end of the previous consolidated fiscal year to ¥149,531 million, mainly due to increases in other components of equity and retained earnings.

(3) Summary of Outlook for Consolidated Financial Forecast

In the nine months ended September 30, 2025, as the business performance is almost in line with the original plan, the Group has decided to leave the consolidated financial forecast unchanged at this time. Given the high degree of continued uncertainty in the business environment, the Group will promptly disclose any revisions required by sudden market changes. The assumed foreign exchange rates in the financial forecast are ¥150/US$ and ¥160/€.

2. Condensed Quarterly Consolidated Financial Statements and Major Notes

(1) Condensed Quarterly Consolidated Statement of Financial Position

(Millions of yen)

	As of December 31, 2024	As of September 30, 2025
Assets		
Current assets		
Cash and cash equivalents	34,663	32,531
Trade and other receivables	70,644	69,716
Other short-term financial assets	2,047	1,676
Inventories	57,501	61,649
Income taxes refund receivable	707	675
Other current assets	5,838	7,059
Sub total	171,403	173,308
Assets held for sale	8,734	486
Total current assets	180,137	173,794
Non-current assets		
Property, plant and equipment	53,369	49,881
Goodwill and Intangible assets	38,013	35,943
Right-of-use assets	24,013	28,260
Investments accounted for using equity method	5,120	5,376
Long-term financial assets	20,971	31,285
Deferred tax assets	2,846	2,849
Other non-current assets	1,090	962
Total non-current assets	145,426	154,559
Total assets	325,563	328,354

(Millions of yen)

	As of December 31, 2024	As of September 30, 2025
Liabilities and equity		
Liabilities		
Current liabilities		
Short-term borrowings	9,105	5,634
Trade and other payables	28,915	26,032
Lease liabilities	3,487	3,870
Other short-term financial liabilities	680	673
Income taxes payable	1,494	568
Provisions	1,404	1,629
Other current liabilities	35,665	35,234
Sub Total	80,753	73,643
Liabilities directly associated with assets held for sale	1,900	—
Total current liabilities	82,653	73,643
Non-current liabilities		
Long-term borrowings	75,226	72,037
Lease liabilities	19,395	23,515
Other long-term financial liabilities	109	15
Net defined benefit liabilities	1,227	1,207
Provisions	1,514	878
Deferred tax liabilities	3,067	6,005
Other non-current liabilities	364	1,520
Total non-current liabilities	100,904	105,179
Total liabilities	183,558	178,822
Equity		
Share capital	6,544	6,544
Capital surplus	6,016	6,031
Treasury shares	(2,692)	(2,677)
Other components of equity	34,289	36,639
Retained earnings	95,912	101,168
Equity attributable to owners of the Company	140,070	147,706
Non-controlling interests	1,935	1,825
Total equity	142,005	149,531
Total liabilities and equity	325,563	328,354

(2) Condensed Quarterly Consolidated Statement of Profit or Loss and Condensed Quarterly Consolidated Statement of Comprehensive Income

Condensed Quarterly Consolidated Statement of Profit or Loss

(Millions of yen)

	Nine Months ended September 30, 2024 (From January 1, 2024 to September 30, 2024)	Nine Months ended September 30, 2025 (From January 1, 2025 to September 30, 2025)
Revenue	151,708	152,278
Cost of sales	(110,773)	(107,345)
Gross profit	40,935	44,932
Selling, general and administrative expenses	(37,623)	(37,061)
Other income	1,375	1,374
Other expenses	(948)	(1,034)
Operating profit	3,739	8,211
Financial income	1,104	957
Financial costs	(702)	(1,505)
Share of profit (loss) of associates and joint ventures accounted for using the equity method	481	322
Profit before tax	4,622	7,985
Income tax expenses	(496)	(582)
Profit for the period	4,126	7,402
Profit for the period attributable to:		
Owners of the Company	4,188	7,331
Non-controlling interests	(62)	71
Profit for the period	4,126	7,402
Earnings per share		
Basic earnings per share (Yen)	63.26	110.65
Diluted earnings per share (Yen)	63.18	110.51

Condensed Quarterly Consolidated Statement of Comprehensive Income

(Millions of yen)

	Nine Months ended September 30, 2024 (From January 1, 2024 to September 30, 2024)	Nine Months ended September 30, 2025 (From January 1, 2025 to September 30, 2025)
Profit for the period	4,126	7,402
Other comprehensive income:		
Items that will not be reclassified to profit or loss		
Financial assets measured at fair value through other comprehensive income (loss)	751	6,395
Share of other comprehensive income (loss) of associates and joint ventures accounted for using the equity method	(0)	(3)
Total	751	6,391
Items that may be reclassified to profit or loss		
Exchange differences on translation of foreign operations	839	(4,146)
Gain (loss) on cash flow hedges	(131)	265
Share of other comprehensive income (loss) of associates and joint ventures accounted for using the equity method	99	(103)
Total	807	(3,984)
Other comprehensive income, net of tax	1,558	2,406
Total comprehensive income for the period	5,685	9,809
Total comprehensive income for the period attributable to:		
Owners of the Company	5,630	9,792
Non-controlling interests	54	17
Total comprehensive income for the period	5,685	9,809

(3) Condensed Quarterly Consolidated Statement of Changes in Equity

Nine months ended September 30, 2024 (From January 1, 2024 to September 30, 2024)

(Millions of yen)

	Equity attributable to owners of the parent company				
				Other components of equity	
	Share Capital	Capital surplus	Treasury shares	Financial assets measured at fair value through other comprehensive income	Exchange differences on translation of foreign operations
Balance as of January 1, 2024	6,544	6,113	(2,753)	5,717	19,049
Profit for the period					
Other comprehensive income				751	801
Total comprehensive income for the period	—	—	—	751	801
Purchase of treasury shares			(0)		
Disposal of treasury shares		18			
Dividends					
Share-based payments		(49)	62		
Transfer to retained earnings				(9)	
Others		(77)			
Total transactions with owners	—	(107)	61	(9)	—
Balance as of September 30, 2024	6,544	6,005	(2,691)	6,459	19,850

(Millions of yen)

	Equity attributable to owners of the parent company				Non-controlling interests	Total Equity
	Other components of equity		Retained earnings	Total		
	Profit (loss) in cash flow hedges	Total				
Balance as of January 1, 2024	30	24,797	89,724	124,426	1,862	126,288
Profit for the period			4,188	4,188	(62)	4,126
Other comprehensive income	(111)	1,441		1,441	117	1,558
Total comprehensive income for the period	(111)	1,441	4,188	5,630	54	5,685
Purchase of treasury shares				(0)		(0)
Disposal of treasury shares				18		18
Dividends			(1,986)	(1,986)	(84)	(2,070)
Share-based payments				12		12
Transfer to retained earnings		(9)	9	—		—
Others				(77)		(77)
Total transactions with owners	—	(9)	(1,977)	(2,032)	(84)	(2,116)
Balance as of September 30, 2024	(80)	26,230	91,936	128,024	1,833	129,857

Nine months ended September 30, 2025 (From January 1, 2025 to September 30, 2025)

(Millions of yen)

	Equity attributable to owners of the parent company				
				Other components of equity	
	Share Capital	Capital surplus	Treasury shares	Financial assets measured at fair value through other comprehensive income	Exchange differences on translation of foreign operations
Balance as of January 1, 2025	6,544	6,016	(2,692)	6,846	27,350
Profit for the period					
Other comprehensive income				6,391	(4,219)
Total comprehensive income for the period	—	—	—	6,391	(4,219)
Purchase of treasury shares			(0)		
Disposal of treasury shares		8			
Dividends					
Share-based payments		6	15		
Transfer to retained earnings				(110)	
Total transactions with owners	—	14	15	(110)	—
Balance as of September 30, 2025	6,544	6,031	(2,677)	13,127	23,130

(Millions of yen)

	Equity attributable to owners of the parent company				Non-controlling interests	Total Equity
	Other components of equity		Retained earnings	Total		
	Profit (loss) in cash flow hedges	Total				
Balance as of January 1, 2025	92	34,289	95,912	140,070	1,935	142,005
Profit for the period			7,331	7,331	71	7,402
Other comprehensive income	288	2,460		2,460	(53)	2,406
Total comprehensive income for the period	288	2,460	7,331	9,792	17	9,809
Purchase of treasury shares				(0)		(0)
Disposal of treasury shares				8		8
Dividends			(2,186)	(2,186)	(127)	(2,314)
Share-based payments				22		22
Transfer to retained earnings		(110)	110	—		—
Total transactions with owners	—	(110)	(2,075)	(2,156)	(127)	(2,283)
Balance as of September 30, 2025	381	36,639	101,168	147,706	1,825	149,531

(4) Condensed Quarterly Consolidated Statement of Cash Flows

(Millions of yen)

	Nine Months ended September 30, 2024 (From January 1, 2024 to September 30, 2024)	Nine Months ended September 30, 2025 (From January 1, 2025 to September 30, 2025)
Cash flows from operating activities:		
Profit before tax	4,622	7,985
Depreciation and amortization	8,449	8,276
Impairment losses	818	(49)
Interest and dividend income	(682)	(859)
Interest expenses	698	857
Foreign exchange losses (gains)	53	1,019
Share of profit of associates and joint ventures accounted for using the equity method	(481)	(322)
(Profits) losses on sale and disposal of property, plant and equipment	(454)	688
Losses on sales of shares of subsidiaries and associates (gains)	—	(455)
Decrease (increase) in trade and other receivables	480	(5,681)
Decrease (increase) in inventories	(7,056)	(5,503)
Increase (decrease) in trade and other payables	(1,104)	1,824
Increase (decrease) in contract liabilities	1,666	185
Increase (decrease) in net defined benefit liabilities	(14)	(5)
Other	336	(113)
Subtotal	7,331	7,845
Interest and dividends received	699	863
Interest paid	(658)	(799)
Income taxes paid	(21,133)	(1,841)
Income taxes refund	305	287
Net cash provided by operating activities	(13,455)	6,355
Cash flows from investing activities:		
Payments into time deposits	(135)	(1)
Proceeds from withdrawal of time deposits	21	1
Purchase of property, plant and equipment	(3,405)	(3,261)
Proceeds from sale of property, plant and equipment	1,271	202
Purchase of intangible assets	(291)	(414)
Proceeds from sale of equity instruments	25	167
Proceeds from sale of shares of subsidiaries and associates resulting in change in scope of consolidation	—	5,567
Proceeds from sale of businesses	—	610
Payments made for short-term loans receivable	(4)	(3)
Proceeds from collection of short-term loans receivable	3	3
Other	51	—
Net cash provided by (used in) investing activities	(2,462)	2,872

(Millions of yen)

	Nine Months ended September 30, 2024 (From January 1, 2024 to September 30, 2024)	Nine Months ended September 30, 2025 (From January 1, 2025 to September 30, 2025)
Cash flows from financing activities:		
Proceeds from short-term borrowings	23,223	1,036
Repayments of short-term borrowings	(23,983)	(1,097)
Repayments of lease liabilities	(2,792)	(3,023)
Proceeds from long-term borrowings	35,333	—
Repayments of long-term borrowings	(13,519)	(6,486)
Payments for purchase of treasury shares	(0)	(0)
Dividends paid	(1,986)	(2,186)
Dividends paid to non-controlling interests	(84)	(127)
Net cash used in financing activities	16,191	(11,884)
Effects of exchange rate changes on the balance of cash and cash equivalents held in foreign currencies	539	(715)
(Decrease) increase in cash and cash equivalents	813	(3,372)
Cash and cash equivalents at the beginning of the period	32,304	34,663
Reversal of cash and cash equivalents included in assets held for sale	—	1,239
Cash and cash equivalents included in assets held for sale	(1,080)	—
Cash and cash equivalents at the end of the period	32,037	32,531

(5) Notes to Condensed Quarterly Consolidated Financial Statements

(Notes on the Going Concern Assumption)

Not applicable.

(Segment information)

(1) Reportable segments outline

There are no significant changes in the method for determining reportable segments or in the measurement criteria for segment profit during the nine months ended September 30, 2025.

As a result of an organizational change during the nine months ended September 30, 2025, the certain operation previously classified under the Industrial Unit has been reclassified to the Medical Unit. Accordingly, the figures for the first nine months of the previous fiscal year have also been reclassified to reflect the new reportable segments for comparative purpose.

(2) Segment revenues and performance

Nine Months ended September 30, 2024 (From January 1, 2024 to September 30, 2024)

(Millions of yen)

	Reportable segment			Reconciliations (Note 1)	Per condensed quarterly consolidated financial statements (Note 2)
	Industrial Unit	Medical Unit	Total		
Revenue					
Revenue from external customers	92,678	59,030	151,708	—	151,708
Intersegment revenue or transfers	161	0	161	(161)	—
Total	92,839	59,030	151,870	(161)	151,708
Segment profit (loss)	4,268	2,287	6,555	(2,816)	3,739
Other items					
Financial income					1,104
Financial costs					(702)
Share of profit (loss) of associates and joint ventures accounted for using the equity method					481
Profit before tax					4,622

(Note)

1. The segment profit reconciliation consists of ¥(2,949) million as corporate expenses not allocated to a reportable segment and ¥132 million as eliminations of intersegment transactions. The corporate expenses are mainly general and administrative expenses not attributable to the reportable segments.
2. Segment profit is reconciled to operating profit as presented in the condensed quarterly consolidated statement of profit or loss.

Nine Months ended September 30, 2025 (From January 1, 2025 to September 30, 2025)

(Millions of yen)

	Reportable segment			Reconciliations (Note 1)	Per condensed quarterly consolidated financial statements (Note 2)
	Industrial Unit	Medical Unit	Total		
Revenue					
Revenue from external customers	95,941	56,336	152,278	―	152,278
Intersegment revenue or transfers	201	―	201	(201)	―
Total	96,142	56,336	152,479	(201)	152,278
Segment profit (loss)	7,257	3,784	11,042	(2,830)	8,211
Other items					
Financial income					957
Financial costs					(1,505)
Share of profit (loss) of associates and joint ventures accounted for using the equity method					322
Profit before tax					7,985

(Note)

1. The segment profit reconciliation consists of ¥(3,415) million as corporate expenses not allocated to a reportable segment, ¥129 million as eliminations of intersegment transactions, and ¥455 million as gains on sales of shares of subsidiaries and associates. The corporate expenses are mainly general and administrative expenses not attributable to the reportable segments.
2. Segment profit is reconciled to operating profit as presented in the condensed quarterly consolidated statement of profit or loss.